Hemostats and Tissue Sealants Market (Product Type - Topical Hemostats, and Tissue Sealants and Adhesives; End-use Industry - Hospitals and Clinics, Specialty Clinics, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Hemostats and Tissue Sealants Market (Product Type - Topical Hemostats, and Tissue Sealants and Adhesives; End-use Industry - Hospitals and Clinics, Specialty Clinics, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Report Code: IGR01420 Category: Healthcare & Medical Devices Published: May, 2024

A recent report published by Infinium Global Research on hemostats and tissue sealants market provides in-depth analysis of segments and sub-segments in the global as well as regional hemostats and tissue sealants market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional hemostats and tissue sealants market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global hemostats and tissue sealants market.

Market Insight:

The global hemostats and tissue sealants market was valued at USD 6423.31 million in 2028 and is expected to reach USD 12026.56 million by 2030 and grow at a CAGR of 8.19% over the forecast period 2023-2030.

Hemostatic agents and tissue sealants are frequently employed in reconstruction during surgical repair, to stop excessive blood loss. Thrombin sealant, fibrin glue, bovine serum/albumin/glutaraldehyde, and gelatin matrix are some major products offered in the market. Each of these agents has a unique mechanism, price, and use. There are different types of diseases that are treated by different surgeries, but surgery has long been concerned about blood loss. There have long been techniques to stop bleeding and mend wounds. Numerous hemostatic medications and tissue sealants have been created during the past 20 years and are being utilized in a variety of surgical specialties. Hemostatic agents are designed to halt bleeding either through mechanical means or by enhancing the natural coagulation cascade. On the other hand, tissue sealants are products that adhere to and seal defects in tissue, promoting hemostasis and facilitating the healing process. The hemostatic agents function by physically blocking or promoting clot formation, while tissue sealants work by creating a barrier that supports tissue repair and regeneration. The selection of the appropriate agent depends on the specific clinical situation and the patient's individual needs. Healthcare professionals must carefully consider the characteristics of each product and their potential benefits and risks when deciding on the most appropriate treatment option.

The global hemostats and tissue sealants market is witnessing significant growth due to the increasing number of surgical procedures, the rising prevalence of chronic diseases, and advancements in technology. Hemostats are used to control bleeding during surgical procedures, while tissue sealants are used to close wounds and prevent blood loss. The market is also driven by the increasing demand for minimally invasive surgical procedures, which require the use of hemostats and tissue sealants to minimize blood loss and reduce the risk of infection. The growing aging population is also contributing to the growth of the hemostats and tissue sealants market. Elderly people are more prone to chronic diseases and require surgical procedures, which increases the demand for hemostats and tissue sealants.

Research Methodology Brief:

This research has been performed by using excessive primary and secondary research methods. The primary research has been conducted by interviewing several executives and consultants operating in the hemostats and tissue sealants sector and allied industries. The information has also been collected using the most prominent primary method which is interviews. This involves the application of questioners to dig for insights from industry experts. Moreover, the secondary research has helped us validate the research findings through primary research. The analyst has browsed through healthcare sector publications, entertainment industry reports, and government data to track trends in popular procedures, destination countries, and revenue growth.

The market size has been identified and triangulated using both bottom-up and top-down approaches. In the bottom-up approach, the rising application of hemostats and tissue sealants in different hospitals across the globe in various countries is estimated. This helps accumulate the country's market size, which is then added up to get the regional market size. With the top-down approach, the regional estimated market size is divided among regions and the key hemostats and tissue sealants producers. The revenues were distributed among the sub-segments in the hemostats and tissue sealants market in the regional analysis such as North America, Europe, APAC, and the Rest of the World. The revenue distribution in the global hemostats and tissue sealants market can be estimated by analyzing the revenue generated by different hemostats and tissue sealants segments in each region and further in each country under the region. This approach helped us to triangulate the market and estimate the regional as well as country market size of the global hemostats and tissue sealants market.

Key Insights into the study:

The prevalence of cardiovascular diseases is anticipated to contribute to the growth of the hemostats and tissue sealants market over the projected period. Rising patients suffering from different types of cardiovascular diseases such as coronary heart disease (CHD), stroke, heart failure, and other conditions affecting the heart and blood vessels. According to a report by the New York State Department of Health in 2022, every year about 697,000 people die of heart disease in the United States. This means 1 in every 5 deaths is caused by heart disease. Coronary heart disease (CHD) is the most common type of heart disease, killing cardiovascular diseases approximately 382,820 people annually. Every year about 805,000 Americans have a heart attack. Out of heart attack cases, 605,000 are a first heart attack and 200,000 happen in people who have already had a heart attack back in time. In addition, according to a report published by the World Heart Federation (WHF) in 2030, cardiovascular diseases (CVDs) are the leading cause of death globally, in 2021, CVDs accounted for 20.5 million deaths. The rising cardiovascular diseases support the growth of the hemostats and tissue sealants market as it is used to help control bleeding and ensure proper wound closure. Thus, increasing cases of heart attacks are responsible for the growth of the hemostats and tissue sealants market. Moreover, a number of people go through several types of general surgeries across the globe to treat different types of diseases. In general surgery, an appendectomy is among the most common surgery. The tissue sealants used in general surgeries such as appendectomy promote wound healing, seal the incision site after removal of the appendix, and reduce the risk of complications. Additionally, hemostats and tissue sealants are used to seal incisions in bowel surgeries, hernia repair surgeries, hysterectomies, and gallbladder removal surgeries. Surgical sealants are used in these surgeries as adjuncts to sutures to prevent air and liquid leakages. The rising number of general surgeries is likely to promote the growth of the market in the U.S. For instance, every year about 500,000 women in the United States have a hysterectomy and about 460,000 U.S. residents go through gallbladder removal surgeries. The extensive use of hemostats and tissue sealants is due to many reasons such as minimized blood loss, better closure, faster implementation, and easy and less painful operation without the need for removal. The benefits provided by sealants are responsible for their extensive use. Moreover, modern plastic surgery has gained popularity among the population across the globe. According to the International Society of Aesthetic Plastic Surgery, in 2022, plastic surgeons performed a notable 11.2% rise in the total number of surgical procedures, surpassing 14.9 million surgical and 18.8 million non-surgical interventions worldwide. In addition, according to the latest annual statistics from the American Society of Plastic Surgeons, nearly USD 16.7 billion was spent on cosmetic procedures in the U.S. in 2020. In the same year, the United States registered the highest number of cosmetic procedures across the world, with nearly four million operations. The most popular surgical cosmetic procedure worldwide in 2020 was breast augmentation . These surgeries include the use of hemostats and tissue sealants, the rising number of general surgeries across the globe further contributes to the expansion of the market during the projected period.

However, the use of hemostatic agents may cause adverse reactions such as foreign body reactions, inflammation, and infections, which can impede the wound healing process. Consequently, surgeons must exercise caution in selecting appropriate hemostatic agents based on their mechanisms, benefits, drawbacks, and effects on wound healing. Proper use and application of hemostatic agents can help minimize complications and support optimal wound healing outcomes. The disadvantages of tissue sealants include lower tensile strength and the potential for systemic absorption or embolization. Moreover, an individual may develop allergic reactions to the ingredients present in hemostats and tissue sealants. These reactions can manifest in the form of itching, rashes, hives, or breathing difficulties. In some cases, the use of hemostats and tissue.

Numerous companies worldwide are making substantial investments in the field to advance and develop new products. This trend is expected to create growth opportunities for the market in the projected period. For instance, in July 2021, Medcura, Inc. a commercial-stage medical device company, and ASO, LLC a major U.S. manufacturer and supplier of first aid products, announced the launch of Rapid-Seal®, an advanced antibacterial hemostatic gel that promises high performance and efficacy. Medcura's Food and Drug Administration (FDA) cleared wound gel to enter the market. The products are able to provide rapid bleeding management and antibacterial capabilities to enhance wound treatment and also help to fight infections of the wound and promote an environment for safe healing. Additionally, in July 2021, Baxter International Inc. a global medical products company, announced its Baxter Healthcare Corporation subsidiary has completed the acquisition of certain assets from CryoLife, Inc. related to PerClot Polysaccharide Hemostatic System. The deal has been done for up to USD 60.8 million. The strategy of Boxter behind acquiring products and technologies to augment the company’s leading portfolio across the hospital. PerClot has a global commercial presence in more than 35 countries across the world, which helps to expand the geographical presence of the company. Thus, the increasing spending on the development of new products along with mergers and acquisition practices are providing lucrative growth opportunities for the hemostats and tissue sealants market over the years.

Global Hemostats and Tissue Sealants Market Report 2030 | IGR

The global hemostats and tissue sealants market covers the analysis of regions such as North America, Europe, APAC, and the rest of the world. The North America region accounted for the highest share in the global hemostats and tissue sealants market, generating revenue of USD 3063.32 million in 2022, and is expected to grow with the highest CAGR of 7.70% over the forecast period 2023-2030.

The hemostats and tissue sealants markets in the United States, Canada, and Mexico are dynamic and experiencing robust growth. In the United States, the market is thriving due to the increasing prevalence of chronic diseases and a rising number of surgeries. The emphasis on advanced medical technology and innovations in surgical procedures are driving demand for hemostats and tissue sealants. In Canada, the market is flourishing as it addresses the growing incidence of cardiovascular diseases and the increasing number of surgical interventions. The emphasis on minimally invasive surgeries aligns with broader healthcare trends, boosting the demand for advanced hemostatic and tissue-sealing products. The prevalence of cardiovascular diseases is a significant driver, and the market is further stimulated by the emphasis on efficient bleeding control and tissue repair in surgical procedures. The hemostats and tissue sealant market in Mexico is driven by technological advancements and a rising number of surgeries, surpassing 900,000 in 2020. The country's role as a medical tourism hub, offering advanced medical facilities and skilled healthcare professionals, further contributes to the market's growth. Hemostats and tissue sealants play a crucial role in various surgical procedures, from dental and orthopedic to bariatric and cardiology, aligning with the diverse range of surgeries sought by medical tourists. Overall, these markets collectively underscore the pivotal role of hemostats and tissue sealants in shaping the healthcare landscape across North America. The growing demand for these products reflects their significance in ensuring effective hemostasis, promoting efficient tissue repair, and contributing to improved patient outcomes in diverse surgical interventions.

Report Scope of the Hemostats and Tissue Sealants Market:

Report Coverage Details
Market Size in 2022 USD 6423.31 Million
Market Size by 2030 USD 12026.56 Million
Growth Rate from 2023 to 2030 CAGR of 8.19%
Largest Market North America
No. of Pages 180
Market Drivers
  • The prevalence of cardiovascular diseases is anticipated to contribute to the growth of the hemostats and tissue sealants market over the projected period.

  • The rising number of general surgeries is likely to promote the growth of the market in the U.S.

Market Segmentation By Product Type, and By End-use Industry
Regional Scope North America, Europe, Asia Pacific, and RoW

Segment Covered

The report on global hemostats and tissue sealants market covers segments such as product type, and end use industry. On the basis of product type, the sub-markets include topical hemostats, and tissue sealants and adhesives. On the basis of end use industry, the sub-markets include hospitals and clinics, specialty clinics, and others.

Companies Profiled:

The report provides profiles of the companies in the market such as Integra LifeSciences, Medtronic, Johnson & Johnson (Ethicon), CryoLife, Inc. (Artivion, Inc), Becton, Dickinson, and Company, Baxter International Inc., Hemostasis, LLC, B. Braun Group, Advanced Medical Solutions Group plc (AMS), and Pfizer Inc..

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the hemostats and tissue sealants market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Frequently Asked Questions (FAQ's)

The global hemostats and tissue sealants market was valued at USD 6423.31 Million in 2022.
It is likely to grow at a CAGR of 8.19% during the forecast period 2023-2030.
The global hemostats and tissue sealants market is estimated to reach USD 12026.56 Million by the end of 2030.
North America is anticipated to exhibit high demand for hemostats and tissue sealants market during the forecast period.
Integra LifeSciences, Medtronic, Johnson & Johnson (Ethicon), CryoLife, Inc. (Artivion, Inc), Becton, Dickinson, and Company, Baxter International Inc., Hemostasis, LLC, B. Braun Group, Advanced Medical Solutions Group plc (AMS), and Pfizer Inc..
Individual License
US $2,500
USD Two Thousand Five Hundred
Google translate
© 2024. Infinium Global Research LLP. All Rights Reserved.